Latest Breaking News On - Investment in biotechnology companies - Page 1 : vimarsana.com

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Brings extensive experience in retinal and ophthalmology diseases...

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Opthea Appoints Sujal Shah to the Board of Directors

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee ChairMELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment

Opthea Appoints Sujal Shah to the Board of Directors

Opthea Appoints Sujal Shah to the Board of Directors

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair...

Opthea Appoints Sujal Shah to the Board of Directors

Opthea Reports Half-Year Financial Results And Business Updates

Opthea Reports Half-Year Financial Results and Business Updates

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....